EMA Authorised: Jentadueto (linagliptin;metformin) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA authorised marketing of Jentadueto, a fixed-dose combination of linagliptin and metformin, for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jentadueto (linagliptin/metformin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Boehringer Ingelheim International GmbH. Decision date: 17/12/2025